Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 46fludarabine phosphate 40Tacrolimus 36Busulfan 34Peripheral Blood Stem Cell Transplantation 31Whole-Body Irradiation 29Mycophenolic Acid 27Antilymphocyte Serum 23Methotrexate 22Azacitidine 21Cyclosporine 20Cytarabine 17Melphalan 16Decitabine 16Radiotherapy 14fludarabine 13Methylprednisolone 12Filgrastim 12Cord Blood Stem Cell Transplantation 10Stem Cell Transplantation 8Etoposide 8Biopsy 8venetoclax 7Specimen Handling 7Rituximab 7Injections 7Arsenic Trioxide 7thymoglobulin 6merphos 6Sirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelomonocytic, Chronic × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡